Company intelligence / Profile preview

Sirtsei Pharmaceuticals, Inc.

Morrisville, North Carolina, United Statesarrivobio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

SP-624 (forvisirvat) demonstrated statistically significant and clinically meaningful efficacy in female patients with Major Depressive Disorder in a Phase 2 study. The drug showed improvement on the MADRS total score compared to placebo at Week 4, as well as across multiple clinician- and patient-rated depression scales. The drug was well tolerated.

Therapeutic areas: Psychiatry
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

SP-624

Phase 2

Indications: Major depressive disorder

Beyond the preview

Go deeper on Sirtsei Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sirtsei Pharmaceuticals, Inc..

Explore the full profile